Last reviewed · How we verify
minoxidil 5% solution
Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.
Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle. Used for Androgenetic alopecia (male pattern baldness), Female pattern hair loss.
At a glance
| Generic name | minoxidil 5% solution |
|---|---|
| Also known as | Rogaine®, Regaine® |
| Sponsor | Allergan |
| Drug class | Potassium channel opener |
| Target | ATP-sensitive potassium channels |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Minoxidil opens ATP-sensitive potassium channels in vascular smooth muscle, increasing vasodilation and blood flow to the scalp. This enhanced perfusion delivers more oxygen and nutrients to hair follicles, stimulating them to transition from the telogen (resting) phase to the anagen (active growth) phase, thereby promoting hair regrowth and slowing hair loss.
Approved indications
- Androgenetic alopecia (male pattern baldness)
- Female pattern hair loss
Common side effects
- Scalp irritation
- Dryness of scalp
- Itching
- Unwanted hair growth on face or body
- Tachycardia (with systemic absorption)
Key clinical trials
- Androgenic Alopecia TH07 Clinical Trial (PHASE3)
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia (NA)
- Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia (PHASE2)
- A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes (PHASE1, PHASE2)
- Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
- Minoxidil for Treating White Hair: A Randomized Controlled Trial (PHASE4)
- Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia (NA)
- A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- minoxidil 5% solution CI brief — competitive landscape report
- minoxidil 5% solution updates RSS · CI watch RSS
- Allergan portfolio CI